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Non-coding RNAVersican is an extracellular chondroitin sulfate proteoglycanwhich functions as a structuralmolecule but can also
regulate a variety of cellular activities. This study was designed to explore the roles of versican in the process of
dermal wound repair. To elevate levels of versican, we ectopically expressed the versican 3′-untranslated region
(3′UTR) as a competitive endogenous RNA to modulate expression of versican. We demonstrated that wounds
closed faster in transgenicmice expressing the versican 3′UTR, as compared to those inwildtypemice.We stably
expressed versican 3′UTR in NIH3T3 ﬁbroblasts and found that the 3′UTR-transfected cells showed increased
migratory capacity relative to vector-transfected cells. Interestingly, we found that the 3′UTRs of versican
and β-catenin shared common microRNAs (miRNAs) including miR-185, miR-203*, miR-690, miR-680,
and miR-434-3p. Luciferase assays showed that all of these miRNAs could target the 3′UTRs of both versican
and β-catenin, when the luciferase constructs contained fragments harboring the miRNA binding sites. As a
consequence, expression of both versican and β-catenin was up-regulated, which was conﬁrmed in vitro and
in vivo. Transfection with small interfering RNAs (siRNAs) targeting the versican 3′UTR abolished the 3′UTR's
effects on cell migration and invasion. Taken together, these results demonstrate that versican plays important
roles in wound repair and that versican messenger RNAs (mRNAs) could compete with endogenous RNAs for
regulating miRNA functions.
© 2014 Published by Elsevier B.V.1. Introduction
Wound healing is a complex process that involves an inﬂammatory
response followed by subsequent changes to keratinocyte, ﬁbroblast
and endothelial cells which close the wounded area and regenerate
skin tissue [1,2]. Understanding the molecular mechanisms of wound
healing is essential for developing therapeutic strategies to manage
acute and chronic non-healing wounds [3]. To elucidate the signaling
pathways involved in wound healing, different model systems have
been developed. It is now understood that the physiological functions
of skin and tissue remodeling are strictly controlled by extracellular
matrix (ECM) molecules [4] such as versican, as well as by intricate ge-
netic regulatory networks including miRNA.
Versican is a hyaluronan-binding molecule that belongs to a family
of the large aggregating chondroitin sulfate proteoglycans expressed, microRNA; DMEM, Dulbecco's
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).in the ECM [5,6]. It was originally cloned from human ﬁbroblasts and
chicken limb buds [7]. It is expressed in developing embryonic tissue
aswell as in skin [8]. Versican expression is associatedwith tissue devel-
opment [9]. Versican is the principal chondroitin sulfate proteoglycan in
blood vessels, aswell as in the intima and adventitia ofmost arteries and
veins [10]. In vitro studies have shown that versican modulates cell
adhesion [11], aggregation [12], migration [13], proliferation [14],
morphogenesis [15,16], and tissue angiogenesis [17]. This study was
designed to explore the roles of versican in the process of dermal
wound repair. To elevate levels of versican, we ectopically expressed
the versican 3′-untranslated region (3′UTR) as a competitive endoge-
nous RNA to modulate expression of versican by regulating miRNA
functions.
MicroRNAs are single-stranded RNAs of 18–24 nucleotides in length.
They are transcribed from genomic DNA, producing primary RNA tran-
scripts that contain one or more local hairpin structures. The primary
RNA transcripts are then cropped by the RNase III-type enzyme Drosha,
releasing miRNA precursors into the nucleus. The precursor miRNAs
are then brought to the cytoplasm by Exportin-5, and processed to
produce mature miRNAs. Through partial binding with the 3′-
untranslated region (UTR), mature miRNAs repress gene expression
post-transcriptionally. By silencing mRNA expression, miRNAs have
been shown to have a central role in physiological and pathological
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migration [20], survival [21], invasion [22], morphogenesis [23],
tissue growth [24], angiogenesis [25], tumor development [26], and
metastasis [27].
Recent studies have shown that other cellular components, in partic-
ular non-coding transcripts, can regulate the function of mature
miRNAs. These non-coding RNAs can function as competing endoge-
nous RNAs (ceRNAs) to regulate miRNA functions. This was ﬁrst
demonstrated by the ectopic expression of 3′UTRs which was shown
to regulate the function of endogenous miRNAs [28,29]. Similarly,
ectopic expression of a pseudogene of the tumor suppressor PTEN,
namely PTENP1, could increase PTEN expression and regulate cell
proliferation by competing for PTEN-binding miRNAs [31,32]. Ectopic
expression of long noncoding RNAs functions in a similar way by
competing for miRNA binding and regulating their functions [33]. In
our recent study, we found that transgenicmice expressing our versican
3′UTR construct developed liver tumors by inhibiting the activities of
miR-144, miR-133a, miR-431, and miR-199a*, and up-regulating
expression of ﬁbronectin, CD34, and versican [30].
In this study, we employed a versican 3′UTR stable cell line and a
transgenic mouse as model systems to evaluate the effects of the
versican 3′UTR on the migratory phases of wound healing. We found
that ectopic expression of the 3′UTR promoted wound healing by regu-
lating a number of miRNAs that not only targeted versican but also
shared target sites with the 3′UTR of β-catenin. As a consequence,
expression of versican and β-catenin was enhanced while the activities
of the bound miRNAs were inhibited, leading to a combinatorial effect
on cell migration and wound healing.
2. Materials and methods
2.1. Generation of transgenic mice and wound healing experiment
The versican 3′UTR expression construct was generated as previously
described [29]. The transgenewas released from the plasmid by digestion
with ApaLI and StuI and puriﬁed using agarose gel electrophoresis. Trans-
genic mouse strains were developed by microinjection of versican 3′UTR
fragment into fertilized zygotes of C57BL/6xCBA F2 mouse. Injected eggs
were then implanted into oviduct of female mouse. Transgenic strains
were maintained by backcrossing with C57BL/6xCBA F1 mouse [29]. Pos-
itive transgenic mice were identiﬁed by genotyping using GAPDH as a
control. By the age of 4 weeks, transgenic mice and control group were
subject to skin biopsy with a punch (Miltex), creating a pair of full-
thickness, excisional wound, which had diameters around 5 mm on the
back of the mice. The wound sizes were measured everyday thereafter,
and all mice were sacriﬁced at the seventh day when some wounds
were healed. Tissue samples were harvested for further analysis. The
wound healing procedure was approved by the Animal Use Committee
of Sunnybrook Research Institute.
2.2. Construct generation
In this study, twenty luciferase reporter constructs were generated.
Five were made to conﬁrm targeting of versican 3′UTR by miR-185,
miR-203*, miR-434-3p, miR-680, and miR-690, producing Luc-Ver185,
Luc-Ver203⁎, Luc-Ver434-3p, Luc-Ver680, and Luc-Ver690. For each con-
struct generated, one counterpart constructwasmade, which contained
a mutation site to abolish the targeting by the miRNA, producing Luc-
Ver185-mut, Luc-Ver203⁎-mut, Luc-Ver434-3p-mut, Luc-Ver680-mut, and
Luc-Ver690-mut. Five constructs were generated to conﬁrm targeting
of β-catenin 3′UTR by miR-185, miR-203*, miR-434-3p, miR-680, and
miR-690, producing Luc-Cat185, Luc-Cat203⁎, Luc-Cat434-3p, Luc-Cat680,
and Luc-Cat690. Similarly, ﬁve counterpart constructs were generated,
which containedmutations to abolish targeting by themiRNAs, produc-
ing Luc-Cat185-mut, Luc-Cat203⁎-mut, Luc-Cat434-3p-mut, Luc-Cat680-
mut, and Luc-Cat690-mut.Each construct was generated by two primers as follows. Luc-Ver185
by huVUTR-SacI (5′ gg gagctc tgatccctaaaatggcgaacatgtg) and huVUTR-
R185-MluI (5′ ggg ccc acgcgt ggcc tttc ttg taa gtga), Luc-Ver203⁎ by
huVUTR-SacI and huVUTR-R203-MluI (5′ cc acgcgt cggc aaccc aaaat ga
ct gaa cgg), Luc-Ver434-3p by huVUTR-SacI and huVUTR-R434-3p-MluI
(5′ ggg ccc acgcgt aaa ct aca taaaa gca gcc), Luc-Ver680 by huVUTR-SacI
and huVUTR-R680-MluI (5′ ggg ccc acgcgt at ca tgt agaa gc aaa ct),
and Luc-Ver690 by huVUTR-SacI and huVUTR-R690-MluI (5′ ggg ccc
acgcgt gtttt ct ag ct gt cc agg).
To generate the mutations, each forward primer was combined
with a mutation primer (-mut) as follows: huVUTR-R203*-MluI-mut
(5′ cc acgcgt cggc aaccc aaaat ga ct gaa cgg acc tcca) to generate Luc-
Ver203⁎-mut, huVUTR-R434-3p-MluI-mut (5′ ggg ccc acgcgt aaa ct aca
taaaa gca gcc ctt ccaa) to generate Luc-Ver434-3p-mut, huVUTR-R690-
MluI-mut (5′ ggg ccc acgcgt gtttt ct ag ct gt cc agg tttt gcc) to generate
Luc-Ver690-mut, huVUTR-R680-MluI-mut (5′ ggg ccc acgcgt at ca tgt
agaa gc aaa ct cgt cc ata ggc tg) to generate Luc-Ver680-mut, and
huVUTR-R185-MluI-mut (5′ ggg ccc acgcgt ggcc tttc ttg taa gtga tct
aaaag) to generate Luc-Ver185-mut.
The β-catenin 3′UTR constructs were generated as follows. Luc-
Cat185 was generated by mu-βcatenin-SacI (5′ ggg ccc gagctc
tcctttaggtaagaaagcttat) and mu-βcatenin-R185-MluI (5′ ggg ccc acgcgt
gttc aga cac ta ca gc tgt at aga); Luc-Cat203⁎, by mu-βcatenin-R203*-
SacI (5′ ggg ccc gagctc caagctgagtttcctatgggaacag) and mu-βcatenin-
R203*-MluI (5′ ggg ccc acgcgt tta gtg ttct acacc atta ctc); and Luc-Cat690
by mu-βcatenin-R203*-SacI and mu-βcatenin-R690-MluI (5′ ggg ccc
acgcgt ca tttc ta tc tg tc tat ttat acaa). Two binding sites for miR-434-3p
and miR-680 had a few nucleotides overlapped. Thus, one construct
was generated to cover both binding sites by using mu-βcatenin-R203*-
SacI and mu-βcatenin-R680-MluI (5′ ggg ccc acgcgt gttt aatt ctg aacc
atttc tataa). The names Luc-Cat434-3p and Luc-Cat680 were used in the
ﬁgure for easily following.
The mutation primers were mu-βcatenin-R185-MluI-mut (5′ ggg
ccc acgcgt gttc aga cac ta ca gc tgt at aga ctct aagg, to generate mutation
site formiR-185),mu-βcatenin-R203*-MluI-mut (5′ ggg ccc acgcgt tta gtg
ttct acacc atta ctc ccaa ctt ag, to generatemutation site formiR-203*),mu-
βcatenin-R690-MluI-mut (5′ ggg ccc acgcgt ca tttc ta tc tg tc tat ttat acaa
ttcc ct ac, to generatemutation site formiR-690), andmu-βcatenin-R680-
MluI-mut (5′ ggg ccc acgcgt gttt aatt ctg ttgg atttc tataa ccg gta ctgt, to
generate mutation site for miR-680 and miR-434-3p).
For all construct generation, PCR products were digested with
restriction enzymes SacI and MluI. The fragments were puriﬁed and
inserted into SacI/MluI digested pMir-Report vector. As a negative
control, the vector was inserted with a non-related sequence, which
was ampliﬁed from the coding sequence of the chicken versican G3
domain using 2 primers, chver10051SpeI (5′gggcccactagtaatggagccac
atgtatagat) and chver10350SacI (5′gggcccgagctcgaaatcacgctcaaacatctt).
No signiﬁcant endogenousmiRNA bindingwas expected to occur in this
fragment. These PCR products were then inserted into a SpeI- and a
SacI-digested pMir-Report Luciferase plasmid.
2.3. Real-time PCR
To conﬁrm ectopic expression of versican 3′UTR, total RNA was iso-
lated from transgenic mouse tissues or from the cells transfected with
theVerUTR construct. cDNAwas synthesized using 1 μg RNA. Successive
PCR was performed using 1 μl cDNA as a template. The primers used as
controls for real-time PCR were Human-U6RNAf and Human-U6RNAr
as described in [34].
2.4. Luciferase assay
NIH3T3ﬁbroblastswere cultured in 12-well tissue culture plates at a
cell density of 1 × 105 cells per well in DMEM containing 10% FBS. The
cultures were maintained at 37 °C for 24 h till sub-conﬂuence. The cul-
tures were co-transfected with the versican or β-catenin luciferase
Fig. 1. Enhanced wound healing in VerUTR transgenic mice. (A) VerUTR transgenic and wildtype mice were subject to wound healing tests. One week after the wounding, healed mice
were counted. VerUTR showed higher rate of wounding healing. (B) The unwounded mice were subject to wound size measuring. The VerUTR transgenic mice showed enhanced
wound healing as compared with the wildtype mice. (C) Picture taken from the seventh day showed that the VerUTR transgenic mice had enhanced wound healing compared with
the wildtype. (D) Wound repair was followed closely in the course of healing process. The wounds closed signiﬁcantly faster in the VerUTR transgenic mice than in the wildtype mice.
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with the corresponding miRNA mimics (from GenePharma, Shanghai,
China) using Lipofectamine 2000 in 500 μl serum-free DMEM. Each
transfection mixture also contained 10 ng pRL-Renilla Luciferase
Reporter Vector. The Renilla plasmid served as an internal control of
transfection efﬁciency to normalize the value of the ﬁreﬂy luciferase ac-
tivities. A negative control construct (G3R) contained a non-related se-
quence ligated to a luciferase reporter, which was also transfected withthe miRNA mimics at the same ratio. All reactions were performed in
triplicate. Six hours after the transfection, the medium in the cultures
was changed to fresh DMEM containing 10% FBS, followed by an addi-
tional incubation of 48 h. The cells were then harvested and luciferase
activity wasmeasured using a Dual-Luciferase® Reporter Assay System
(Promega, Nepean, ON, Canada). In brief, after removing from
the growth media and rinsing with PBS, the cultures were lysed in 1×
Passive Lysis Buffer (150 μl per well). The culture plates were gently
Fig. 2. Analysis of wound repair. (A) Wound tissue samples were subject to H&E staining. Faster close-up of the wound was detected in the VerUTR transgenic mice (arrows). Typical
photos are provided for 2 transgenicmice and 2wildtypemice. Scale bar, 400 μm. (B) Onday 7, smaller amounts ofmussel tissueswere detected in thewildtypemice,while large amounts
of mussel tissues were found in the VerUTR transgenic mice (arrows). Scale bar, 100 μm. (C) The wound surface of the wildtype mice showed thinner layer of blood clot and contained
fewer lymphatic cells than that of the VerUTR transgenicmice (arrows). Scale bar, 50 μm. (D) Thewounds in thewildtypemice containedmuch fewer cells than thewounds in the VerUTR
transgenic mice. Scale bar, 50 μm.
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Eppendorf tubes for centrifugation. 100 μl of luciferase assay Buffer II
was dispensed into luminometer tubes. 20 μl of lysate supernatant
was transferred to each tube and mixed. Fireﬂy luciferase activity was
measured using a luminometer (Berthold, Germany). 100 μl of Stop &
Glo® Reagent was dispensed into each luminometer tube and Renilla
luciferase activity was measured. Relative luciferase activity was com-
pared between the luciferase reporter construct, the mutant luciferase
reporter construct and the negative control construct. Each experiment
was performed in triplicate.
2.5. Immunohistochemistry analysis
Wound tissues were freshly ﬁxed in 10% neutral buffered formalin
overnight and immersed in 70% ethanol. After dehydration, the tissues
were embedded in parafﬁn, and sectioned by microtome (Leica
RM2255). Sections of 4 μm thickness were placed on slides anddeparafﬁnized in xylene twice for 5 min. Slides were rehydrated in
100% ethanol for 3 min, followed by two 5 minute washes in dH2O.
The slides were brought to a pressure cooker in 10 mM sodium citrate
buffer (pH 6.0) and then maintained at a sub-boiling temperature for
10 min to unmask antigenic epitope. After cooling, endogenous peroxi-
dase activity was inhibited by incubating the sections in 3% H2O2 solu-
tion in methanol at 4 °C for 20 min. The sections were rinsed twice in
TBS for 5 min. Non-speciﬁc reactions were blocked with 10% goat
serum at room temperature for 30 min. The slides were then incubated
with a primary antibody solution (diluted in TBS containing 10% goat
serum and 1% BSA) in a humidiﬁed chamber at 4 °C overnight, followed
by three washes in TBS. The slides were then incubated with biotinylat-
ed secondary antibody diluted in TBST at 37 °C for 45 min. ABC reagent
(Vectastain Elite ABC kit, Vector Lab) was prepared according to the
manufacturer's instructions and added to the sections followed by incu-
bation at 37 °C for 45 min. After three 5 minute washes in TBS, DAB
(Peroxidase Substrate Kit, Vector Lab) was added to each section and
Fig. 3. Enhanced expression of Ki67 and CD34 in the VerUTR transgenic mice. Wound tissue samples were subject to immunohistochemistry analysis. Expressions of Ki67 (A) and CD34
(B) increased in the VerUTR transgenic mice samples (arrows). Scale bar, 50 μm. The positive Ki67 cells and CD34 stained blood vessels were quantiﬁed, and the results are provided
beneath the photos.
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followed by counterstaining in Mayer's hematoxylin. After dehydration
in 95% ethanol and xylene, the sections were mounted with coverslips.
2.6. Western blot
SDS-PAGE–Western blot assay was performed as described [35]. In
brief, cell lysates were collected from the cultures and subject to SDS-
PAGE electrophoresis on 10% separating gel (for β-catenin) or 7% gel
(for versican) with a 4% stacking gel. The buffer system was made up
of 1× TG (Tris–glycine buffer, Amresco product) and 1% SDS. The pro-
teins separated on SDS-PAGE were transferred onto nitrocellulose
membranes (Bio-Rad) in 1× TG buffer containing 20% methanol. The
membrane was then incubated in a blocking buffer TBST (10 mM
Tris–Cl, pH 8.0, 150 mM NaCl, 0.05% Tween 20) containing 5% skim
milk powder (TBSTM) for 1 h while being gently shaken at room tem-
perature. The membranes were incubated with primary antibodies at
4 °C overnight. This included antibodies against α-actin (purchased
from Abcam, cat no. Ab5694), vimentin (from Cell Signaling: 3932S),
N-cadherin (from Santa Cruz: Sc1502), ﬁbronectin (from Abcam:
Ab6328), type I collagen (from Abcam: Ab6308), versican (from US
Biological: L1305A), β-catenin (from Cell Signaling: 8480S), CD34(from Abcam: Ab8158), and Ki67 (from BD Bioscience: 550609).
Membranes were then washed in TBST and incubated with the appro-
priate HRP-conjugated secondary antibodies diluted in TBST for 2 h at
room temperature. The bound antibodies were then visualized with a
Chemiluminescent HRP Antibody Detection Kit (HyGLO, Denville
Scientiﬁc Inc.).2.7. Cell migration assay
VerUTR- and vector-transfected NIH3T3 ﬁbroblasts (4 × 105) were
seeded onto 6-well dishes in DMEM containing 10% FBS. The cultures
were maintained at 37 °C till they reached 95% conﬂuence. The
monolayer cultures were treated with 5 μMmitomycin C, a cell growth
suppressor, for 2 h andwounded by a sterile pipette tip to create a 1-
mm cell-free path. Culture medium was removed and the cultures
were washed with PBS, followed by culturing in DMEM containing
10% FBS with 5 μM mitomycin C. Cells were photographed under a
low-magniﬁcation microscope every 24 h. The distance between
the wounding center and the front of the migrating cells (vertical
axis) was measured. The distance of the migration path of at least
50 cells was measured for statistical analysis.
Fig. 4. Enhanced expression of cell signaling andmatrixmolecules in the VerUTR transgenic mice. Wound tissue samples were subject to immunohistochemistry analysis. Expressions of
α-actin, vimentin, N-cadherin, ﬁbronectin, and type I collagen increased in the VerUTR transgenic mice samples (A). Scale bar, 50 μm. The increased levels of the proteins were quantiﬁed (B).
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All experiments were performed in triplicate (or more). The numer-
ical data were subject to independent statistical analysis (unless
otherwise speciﬁed). The results (mean values± SD) of all experiments
were analyzed by Student's t-test. The levels of signiﬁcance was set
at p b 0.05 (*) and p b 0.01 (**).3. Results
3.1. Expression of versican 3′UTR increased dermal wound healing in
transgenic mice
Our previous study showed that expression of the versican V2 iso-
form coding region promoted tumor angiogenesis [36]. Using a novel
approach,we have found that transfectionwith the versican 3′UTR frag-
ment promoted expression of endogenous versican [34]. In this study,
we also employed transgenic mice expressing versican 3′UTR (VerUTR)as a model system. We ﬁrst conﬁrmed that the transgenic mice indeed
expressed higher levels of versican 3′UTR as compared with the
wildtype mice. RNAs isolated from transgenic mice were subject to
real-time PCR to measure levels of versican 3′UTR. It was conﬁrmed
that expression of versican 3′UTR was signiﬁcantly higher in transgenic
mice than in the wildtype mice as we published recently [30]. VerUTR
transgenic and wildtype mice were subject to dermal wound healing
tests. One week after wounding, VerUTR transgenic mice healed signif-
icantly faster than the wildtype mice (Fig. 1A). We found that the
VerUTR transgenicmice showed enhancedwound healing as compared
to thewildtypemice (Fig. 1B). Examination of the unhealed wounds re-
vealed reduced wound sizes in the VerUTR transgenic mice (Fig. 1C).
The wound healing assay was performed in a large number of mice
and the healing process was monitored every day. The assay conﬁrmed
that the wounds closed signiﬁcantly faster in the VerUTR transgenic
mice than in the wildtype mice (Fig. 1D).
Wound tissue samples were subject to H&E staining. Histological
examination revealed characteristics of increased wound repair in the
VerUTR transgenic mice (Fig. 2A). We also found reduced levels of
Fig. 5. Expression of VerUTR enhanced cell migration and decreased cell attachment. (A) Total RNAswere isolated fromNIH3T3 ﬁbroblasts transfectedwith VerUTR or the control vector,
followed by real-time PCR analysis of the expression of the versican 3′UTR. n= 3, **p b 0.01. (B) Upper, VerUTR- and vector-transfected cells (4 × 105) were seeded onto 6-well dishes in
10% FBS/DMEM and maintained at 37 °C till 95% conﬂuence. The monolayer cells were wounded and cultured in 10% FBS/DMEMwith 5 μMmitomycin for migration assays. Cells were
photographed every 24 h. Expression of VerUTR promoted cell migration. **p b 0.01. Error bars indicate SD (n= 3). Lower, typical photos of cell migration. (C) The cells were inoculated
in tissue culture dishes overnight. Cell attachment was examined under a light microscope. The VerUTR cells exhibited decreased cell attachment (upper panel). The number of adhered
cells was quantiﬁed (lower panel). n = 5, **p b 0.01.
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larger amounts of muscle tissues were found in the VerUTR transgenic
mice (Fig. 2B). Thewound surface of the wildtypemice showed thinner
layer of blood clot and contained fewer lymphatic cells in the clot as
compare with that of the VerUTR transgenic mice, which had much
thicker layer of clot and a greater number of lymphatic cells (Fig. 2C).
Examination of cell number revealed much fewer cells in the wound
sites of the wildtype mice than those of the VerUTR transgenic mice
(Fig. 2D). It suggested that the cells in the wound sites of the VerUTR
transgenic mice grew faster than those of the wildtype.
Immunohistochemical analysis of wound tissues revealed an
increased level of Ki67 positive cells in the VerUTR transgenic mice
than in the wildtype (Fig. 3A). Expression of CD34 was also analyzed
to examine blood vessel formation. VerUTR transgenic mouse sam-
ples displayed increased blood vessel formation than the wildtype
(Fig. 3B).Since cytoskeletal proteins and extracellular matrix play important
roles in wound repair, we analyzed expression of a number of these
molecules associated with tissue growth and wound repair. We found
that expression of α-actin, vimentin, N-cadherin, ﬁbronectin, and type
I collagen was elevated in the VerUTR transgenic mice as compared
with that in the wildtype (Fig. 4A). Scanning of the photos with NIH
ImageJ software showed signiﬁcantly higher levels of these proteins in
VUTR mice than in the wildtype (Fig. 4B).
3.2. Versican 3′UTR enhances NIH3T3 cell migration
To test the effects of versican 3′UTR on cell activities, we stably
transfected NIH3T3 ﬁbroblasts with the versican 3′UTR construct or a
control vector. We conﬁrmed expression of the VerUTR construct by
real-time PCR (Fig. 5A). VerUTR-transfected cells were then examined
for their effect using an in vitro wound healing assay. We found that
Fig. 6. Luciferase assays conﬁrming VerUTR targeting. (A) Potential sites in versican 3′UTR targeted by miR-185, miR-203*, miR-434-3p, miR-680, and miR-690. (B) Potential sites in β-
catenin 3′UTR targeted by miR-185, miR-203*, miR-434-3p, miR-680, and miR-69. (C) The 3′UTR fragments of versican were cloned into the luciferase reporter vector pMir-Report
resulting in 5 constructs. Mutated sequences (bold and underlined) were generated in the seed regions to abolish binding of the corresponding miRNAs. (D–H) NIH3T3 ﬁbroblasts
were co-transfected with different miRNA mimics and the luciferase reporter constructs harboring versican or mutant versican 3′UTR fragments. A non-related fragment of cDNA was
used as a control. Luciferase activity assays indicated that all 5 miRNAs, miR-185 (D), miR-203* (E), miR-434-3p (F), miR-680 (G), and miR-690 (H) repressed luciferase activities
when it harbored the corresponding versican 3′UTR comparedwith the control (ctrl), whichwere reversedwhen the potentialmiRNA target sitewasmutated. n=3, *p b 0.05, **p b 0.01.
1380 W. Yang, A.J.M. Yee / Biochimica et Biophysica Acta 1843 (2014) 1373–1385VerUTR-transfected cells showed increased migration into the wound-
ed areas relative to the control cells (Fig. 5B). We also found that the
VerUTR-transfected cells adhered to tissue culture plates slower than
the vector control after cell inoculation (Fig. 5C). This appeared to be
consistent with increased cell migration.
3.3. Versican 3′UTR regulates miRNA functions
Analysis with computational algorithms revealed many potential
binding miRNAs on the versican 3′UTR. We hypothesized that overex-
pression of the versican 3′UTR would bind and arrest the function of
these miRNAs, resulting in increased versican expression. In addition,
these miRNAs could also bind to mRNAs associated with wound repair,
resulting in up-regulation of the associated molecules. We listed all
these miRNAs and checked their potential targets associated with
wound repair. We found that ﬁve miRNAs, miR-185, miR-203*, miR-
434-3p, miR-680, and miR-690, showed potential binding sites onversican 3′UTR (Fig. 6A). These miRNAs also showed potential binding
sites on β-catenin (Fig. 6B).
We hypothesized that overexpression of the versican 3′UTR would
bindmiR-185, miR-203*, miR-434-3p, miR-680, andmiR-690. As a con-
sequence, the function of these ﬁve miRNAs normally expressed by the
cells would be arrested. As a result, the endogenous mRNAs of versican
and β-catenin were free of targeting by these miRNAs, resulting in in-
creased expression of versican and β-catenin (Supplementary Fig. S1).
To conﬁrm the direct targeting of miR-185, miR-203*, miR-434-3p,
miR-680, and miR-690 on versican 3′UTR, a series of luciferase assays
were performed with each miRNA. Luciferase expression constructs
were generated, each containing a versican 3′UTR fragment harboring
the target sites of these miRNAs, resulting in Luc-Ver185, Luc-Ver203⁎,
Luc-Ver434-3p, Luc-Ver680, and Luc-Ver690. In addition, ﬁve mutant con-
structs were generated, in which each of the potential target sites was
mutated, resulting in Luc-Ver185-mut, Luc-Ver203⁎-mut, Luc-Ver434-3p-
mut, Luc-Ver680-mut, and Luc-Ver690-mut. The mutated sequences are
Fig. 7. Luciferase assays conﬁrming β-catenin targeting. (A) The 3′UTR fragments of β-cateninwere cloned andmutationswere generated as shown. (B–F) Luciferase assays indicated that
all 5 miRNAs repressed luciferase activities when it harbored the corresponding β-catenin 3′UTR comparedwith the control (ctrl), whichwere reversedwhen the potential miRNA target
site was mutated. n = 3, *p b 0.05, **p b 0.01.
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Supplementary Fig. S2.
In the luciferase assays, all predicted miRNAs were found to bind to
the versican 3′UTR linked to the luciferase reporter construct resulting
in repression of luciferase activities (Fig. 6D–H).When themiRNA bind-
ing sites were mutated, there was a restoration in luciferase activity.
To conﬁrm the targeting ofmiR-185,miR-203*,miR-434-3p,miR-680,
and miR-690 on β-catenin 3′UTR, ﬁve luciferase constructs, Luc-Cat185,
Luc-Cat203⁎, Luc-Cat434-3p, Luc-Cat680, and Luc-Cat690, were generated,
each containing a fragment of β-catenin 3′UTR, which harbored the
target sites of these miRNAs. Five mutant constructs, Luc-Cat185-mut,
Luc-Cat203⁎-mut, Luc-Cat434-3p-mut, Luc-Cat680-mut, and Luc-Cat690-
mut, were generated, in which each of the target site was mutated
(Figs. 7A, S3). Luciferase activity assays indicated that all predicted
miRNAs bound to the β-catenin 3′UTR linked to the luciferase reporter
construct, resulting in decreased luciferase activities (Fig. 7B–F). When
the miRNA binding sites were mutated, normal luciferase activities
were restored.We conﬁrmed expressionof the versican3′UTRcompeting
miRNAs, including miR-185, miR-203*, miR-434-3p, miR-680, and
miR-690, in wildtype and transgenic mice as well as in mock- and
versican 3′UTR-transfected NIH3T3 ﬁbroblasts. Although they were
found expressed at different levels, all of them could be detected in
the mice and the cells (Supplementary Fig. S4).
3.4. Conﬁrmation of versican 3′UTR effects
In this study, we hypothesized that expression of versican 3′UTR
would compete with endogenous versican and ß-catenin for miRNA
binding. To test this hypothesis, we analyzed expression of both
versican and ß-catenin in the VerUTR transgenic and wildtype mice,
and subject both to wound healing assays. It was found that the levels
of versican and ß-catenin were higher in the VerUTR transgenic micethan in the wildtype mice (Fig. 8A). Cell lysate was also prepared from
cells transfected with VerUTR or the control vector and subject to
Western blot analysis probed with an anti-versican antibody. Transfec-
tion with VerUTR was found to promote versican expression (Fig. 8B).
Similarly,when probedwith anti-β-catenin antibody, VerUTR cell lysate
also revealedhigher levels ofβ-catenin than the control (Fig. 8C). To test
the effect of versican and β-catenin on cell migration, we transfected
NIH3T3 ﬁbroblasts with siRNAs targeting endogenous versican and
β-catenin and found that silencing versican (Fig. 8D) and β-catenin
(Fig. 8E) decreased cell migration.
Small-interfering RNA (siRNA) sequences were designed to bind to
the versican 3′UTR region. An unrelated oligo was used as a control.
The effects of the siRNA were tested. Western blot analysis was per-
formed and the siRNA treated cells were found to express decreased
levels of versican (Fig. 9A, upper). As well, expression of β-catenin
was down-regulated by siRNA transfection (Fig. 9A, lower). The siRNAs
were then used for functional assays. In cell migration assay, we detected
decreased migration activity in the VerUTR cells transfected with the
siRNA compared with the control oligo (Fig. 9B, Supplementary Fig. S5).
4. Discussion
Our study showed that the ectopic expression of the versican 3′UTR
led to increased expression of endogenous versican.Modulating endog-
enous microRNA provides an ideal approach to study the functions of
this large proteoglycan. This technique allows the study of the overex-
pression of versican with normal physiological functions. Interestingly,
ectopic expression of the versican 3′UTR was also shown to enhance
β-catenin expression. Since β-catenin has been found to regulate
versican expression through promoter interactions [37], our experi-
ments have characterized a novel feedback loop by which β-catenin
and versican levels are continuously regulated. The 3′-untranslated
Fig. 8. Promotion of versican and β-catenin expression. (A) The wounded tissue sections were immunohistochemically stained with antibody against versican and β-catenin. VerUTR
transgenic sections showed higher levels of these proteins than the control sections (upper). The intensity of staining was quantiﬁed using NIH ImageJ software (lower). Scale bar,
50 μm. (B) Cell lysate prepared from cells transfectedwith VerUTR or the control vectorwas subject toWestern blot analysis probedwith anti-versican antibody. Transfectionwith VerUTR
promoted versican expression. (C) The lysate was also probed with anti-β-catenin antibody. Transfection with VerUTR promoted β-catenin expression. (D) NIH3T3 ﬁbroblasts were
transfectedwith three siRNAs targeting endogenousversican for cellmigration assay. Silencing versican decreased cellmigration. n=3, **p b 0.01. (E)NIH3T3ﬁbroblastswere transfected
with three siRNAs targeting endogenous β-catenin for cell migration assay. Silencing β-catenin decreased cell migration. n = 3, **p b 0.01.
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expression through canonical miRNA functioning, also acts to co-
regulate transcripts which are targeted by the same pool of miRNAs.
Among others [29], this included the mRNA of β-catenin. We demon-
strated that both the versican 3′UTR and β-catenin 3′UTR shared com-
mon binding sites for miR-185, miR-203*, miR-434-3p, miR-680, and
miR-690. It appeared that over-expression of the versican 3′UTR
bound and inhibited the activity of these miRNAs, resulting in promo-
tion of versican expression and β-catenin expression. Through various
in vitro and in vivo functional assays, we found that ﬁbroblastmigration
and dermal wound healing process were promoted. The physiological
relevance of our study is strongly supported by the literature showing
that up-regulation of versican and β-catenin plays important roles in
cell migration and wound repair.Versican was originally cloned from human ﬁbroblasts [38] and
developing chicken limbs [7]. Versican is also expressed in many other
tissues including embryos, the developing retina, skin, hair follicles,
and arterial smoothmuscles [39–42]. It has been reported that versican
can associate with a number of ECM and cell surface molecules
[10,43,44], including hyaluronan [10], tenascin [45], ﬁbulin-1 [46],
ﬁbronectin [44], CD44, L-selectin [47], ﬁbrillin [48], and β1-integrin
[49]. With the interaction with these cell surfaces or extracellularmole-
cules, versican can form a pericellular coat to support cell adhesion and
migration [5,50,51]. Due to the interaction of versican and its associated
molecules with water, a hydrated gel can be formed to support cell
migration and wound repair [52].
The promotion of versican on wound repair was also supported by
its direct roles in a variety of cellular activities. Ectopic expression of a
Fig. 9. Conﬁrmation of versican 3′UTR effects. (A) The NIH3T3 cells expressing VerUTR
were transfected with siRNAs against versican 3′UTR. Cell lysates prepared from
siRNA-treated cells were subject to Western blot analysis. The levels of versican
(upper) and β-catenin (lower) decreased as a result of siRNA targeting VerUTR.
(B) NIH3T3 ﬁbroblasts expressing VerUTR were transfected with siRNAs against
versican 3′UTR. Cell migration assays were conducted and it was found to have a
decreased rate of migration compared with the control. n = 3, **p b 0.01.
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was found to enhance cell proliferation, while deletion of the EGF-like
motifs from the versican G3 domain reduced this effect on cell growth
[53]. Overexpression of versican G1 domain construct is shown to
reduce cell adhesion and increase cell proliferation [11,13]. Versican
G3 domain can bind to β1-integrin and mediates cell adhesion [49].
When expressed in NIH3T3 cells, the V1 isoform of versican can en-
hance cell proliferation and protect cells from apoptosis [54]. In addi-
tion, expression of the V1 isoform can induce mesenchymal–epithelial
transition (MET) in NIH3T3 ﬁbroblasts [16]. This was associated with
morphological changes and dramatic alterations in both membrane
and cytoskeleton architectures. Molecular analysis showed that V1
promoted a “switch” in cadherin expression from N- to E-cadherin,
resulting in epithelial speciﬁc adhesion junction. Thus, increased
expression of versican not only enhanced cell migration and wound
repair, but also facilitated a variety of cell activities in ﬁbroblasts associ-
atedwith thewound healing process. Inwound healing,ﬁbroblasts play
a crucial role in wound closure. Fibroblasts are responsible for mostcollagen and elastin syntheses, as well as organization of the ECM
components.
β-Catenin is extensively expressed in tissues and serves diverse func-
tions. Structurally,β-catenin is localizedmainly to the adherens junctions,
where it is bound to the cytoplasmic domain of E-cadherin andmediates
cell–cell adhesion [55]. While forming the complex with E-cadherin, β-
catenin mediates the canonical WNT signaling pathway [56]. After
being activated, β-catenin translocates to the nucleus where it binds to
the TCF/LEF family of transcription factors and triggers expression of the
target genes. The signaling pathway of WNT/β-catenin complex
plays roles in tissue injury and repair [57]. In addition, β-catenin
also mediates TGF-β1 signaling pathway in wound healing [58].
TGF-β1 can substantially activate β-catenin signaling in primary
ﬁbroblast cultures [59]. TGF-β1-mediated ﬁbroblast proliferation
and migration are dependent on β-catenin expression, conﬁrming
the central roles of β-catenin in wound repair [60]. In addition,
TGF-β1 can also enhance versican synthesis [61], and thus plays a
role in wound repair.
In mesenchymal stem cells, TGF-β1 activates β-catenin signaling
pathway to control the self-renewal and osteogenic differentiation of
mesenchymal stem cells [62]. TGF-β1 can lead to the disassembly of
the β-catenin/cadherin complex and facilitate cell migration [56]. In
bone fracture repair, β-catenin plays an important role in the healing
process [63]. WNT/β-catenin singaling can also enhance bone mass
and density [64]. In emphysema, decreased β-catenin signaling causes
dysfunctional repair [65]. In animal and patients with acute lung injury,
up-regulation of β-catenin was found to play roles in the healing pro-
cesses [66,67]. Inhibition of β-catenin signaling impairs epithelial repair
[66]. However, mutation of AXIN2, in a component of the signaling
pathway, stabilizes β-catenin and activates β-catenin/T-cell factor
signaling, leading to the development of colorectal cancer [68]. It is
conceivable that up-regulation ofβ-catenin expression by ectopic trans-
fection of versican 3′UTR would promote cell migration and tissue
repair. Our study has raised a point for further consideration: whether
transcripts that encode proteins with similar functions or proteins in
the same signal pathway can bind to common miRNAs, forming a
signaling network for gene regulation. This awaits further investigation.
To uncover the mechanism by which expression of versican 3′UTR
promoted cell migration and wound healing, we screened for miRNAs
that targeted versican as well as related molecules playing similar
roles leading to these phenotypes. By using the computational
algorithm FindTar (http://bio.sz.tsinghua.edu.cn/ﬁndtar), a long list of
miRNAs was revealed.We then analyzedmiRNAs that could potentially
target molecules playing similar roles in cell migration and wound
healing. Interestingly, β-catenin 3′UTRwas found to share ﬁve common
miRNAs with versican 3′UTR including miR-185, miR-203*, miR-434-3p,
miR-680, and miR-690. While the functions of miR-434-3p, miR-680,
and miR-690 have not been reported, miR-203 is understood to be a
skin-speciﬁc microRNA [69]. miR-203 can promote epidermal differenti-
ation and restrict proliferative potential of keratinocytes, thus inducing
cell-cycle exit. This result suggests that increased activity of miR-203
may in fact slow down tissue repair. Our results indicate that versican
3′UTR expression enhanced cell migration and wound repair. Since
miR-203 was among the miRNAs binding to versican 3′UTR, arresting
the functions of this skin-speciﬁcmiRNAwould predictably be associated
with enhanced cell migration and wound repair [69]. In addition, among
the miRNAs involved in this study, miR-185 has attracted extensively at-
tention. miR-185 can induce cell cycle arrest and suppress cell growth
[70]. It can also target c-Myc, RhoA and Cdc42 and inhibit cell prolifera-
tion [71,72]. Thus, it appears that expression of the versican 3′UTR
could enhance wound repair by repressing miR-185 activity.
Our study also raises the question of the role of the versican
3′untranslated region in ﬁbrotic wound healing. In addition to the
effects of β-catenin on TGF-β1 signaling and versican signaling, we
characterize a novel feedback loop by which the versican 3′UTR up-
regulated signaling proteins upstream of versican. This has implications
1384 W. Yang, A.J.M. Yee / Biochimica et Biophysica Acta 1843 (2014) 1373–1385in pathological ﬁbrosis, which awaits further study. Indeed, versican,
TGF-β1 and β-catenin signaling have been implicated in various levels
of tissue ﬁbrosis [73]. Understanding the functions of whole transcripts
will be invaluable in gene targeting and therapeutic development. Our
work demonstrates the importance of RNA signaling networks in
wound healing, both in vitro and in vivo.
In conclusion, we have demonstrated that ectopic expression of
versican 3′UTR promoted cell migration and wound repair by arresting
the activities of the binding miRNAs. This led to the increased expres-
sion of β-catenin. Increased expression of both versican and β-catenin,
through repression of miRNA activity, facilitated cell migration and
wound repair. Using this approach, it becomes possible to manipulate
the function of any endogenous mature miRNAs.
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